Four years after the government severely restricted its use, the lung cancer drug Iressa may be poised to make a comeback: A study concludes it can slow the deadly disease better than standard chemotherapy in certain patients.
"A drug that takes advantage of cancer cells's appetite for the vitamin folate helped keep lung cancer at bay in 30 percent of patients with advanced disease, the chief executive of Endocyte said on Monday."
"The widespread use of expensive cancer drugs to prolong patients’ lives by just weeks or months was called into question by an article published Monday in the Journal of the National Cancer Institute."
